pegulicianine acetate · Lumicell · NDA 214511
Lumisight
Earliest generic entry, as listed
14 Sep 2034
Blocked by patent: US 9763577.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9763577 | substance, product, use U-3890 | 14 Sep 2034 |
| US 10285759 | use U-3890 | 8 Dec 2031 |
| US 9032965 | use U-3890 | 8 Dec 2031 |
| US 9532835 | use U-3890 | 8 Dec 2031 |
| US 9155471 | use U-3890 | 12 Oct 2031 |
| US 11592396 | substance | 1 Sep 2030 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 17 Apr 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214511 · 001 · RLD | powder, intravenous | EQ 39MG BASE/VIAL | 14 Sep 2034 |